Orion Oyj Logo

Orion Oyj

Develops and manufactures human/vet pharma, APIs, and generics for global markets.

ORNAV | HE

Overview

Corporate Details

ISIN(s):
FI0009014377 (+1 more)
LEI:
74370029VAHCXDR7B745
Country:
Finland
Address:
Orionintie 1, FI-02200 ESPOO
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Orion Oyj is a globally operating Finnish pharmaceutical company that develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs). With a history of over a century, the company focuses on 'building well-being' by translating scientific research into novel therapies and treatments. Orion's research and development efforts are primarily concentrated on specific therapeutic areas, including oncology and pain management. In addition to its portfolio of proprietary drugs, the company also produces generic products and self-care items. Its subsidiary, Fermion, is a key manufacturer of APIs for both Orion and external customers worldwide. Orion also engages in contract manufacturing and the development of diagnostic tests.

Social Media

This is a Fraction of the Available Data.

You're viewing a limited, static snapshot. Professionals use our API to get real-time, AI-ready data for Orion Oyj and 9,000+ other companies.

Stop analyzing yesterday's news. Start building a real-time advantage.

Request Enterprise API Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-08-20 08:00
Share Issue/Capital Change
337 000 kpl Orion Oyj:n A-osaketta muunnettu B-osakkeiksi
Finnish 2.7 KB
2025-08-20 08:00
Share Issue/Capital Change
337,000 Orion Corporation A shares converted into B shares
English 2.8 KB
2025-08-08 08:30
Director's Dealing
Orion Oyj: Johtohenkilöiden liiketoimet - Juhani Kankaanpää
Finnish 4.9 KB
2025-08-08 08:30
Director's Dealing
Orion Corporation: Managers' transactions - Juhani Kankaanpää
English 4.8 KB
2025-08-04 15:10
Director's Dealing
Orion Oyj: Johtohenkilöiden liiketoimet - Satu Ahomäki
Finnish 3.5 KB
2025-08-04 15:10
Director's Dealing
Orion Corporation: Managers' transactions - Satu Ahomäki
English 3.5 KB
2025-07-18 11:00
Interim Report
Orion-konsernin puolivuosikatsaus tammi-kesäkuu 2025
Finnish 18.4 KB
2025-07-18 11:00
Earnings Release
Orion Group Half-Year Financial Report January-June 2025
English 18.3 KB
2025-07-18 08:30
Report Publication Announcement
Orion-konsernin tulosjulkistukset ja yhtiökokous vuonna 2026
Finnish 3.4 KB
2025-07-18 08:30
Report Publication Announcement
Orion Corporation's financial reporting and Annual General Meeting in 2026
English 3.6 KB
2025-07-09 12:00
Management Discussion and Analysis
Sisäpiiritieto: Orion parantaa näkymäarviota vuodelle 2025
Finnish 3.5 KB
2025-07-09 12:00
Earnings Release
Inside information: Orion upgrades full-year outlook for 2025
English 3.6 KB
2025-06-23 08:30
Declaration of Voting Results & Voting Rights Announcements
141 959 kpl Orion Oyj:n A-osaketta muunnettu B-osakkeiksi
Finnish 2.7 KB
2025-06-23 08:30
Declaration of Voting Results & Voting Rights Announcements
141,959 Orion Corporation A shares converted into B shares
English 2.8 KB
2025-05-08 14:30
Major Shareholding Notification
Orion Corporation: Disclosure Under..
Finnish 5.6 KB

Automate Your Workflow. Get a real-time feed of all Orion Oyj filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Orion Oyj via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
2cureX AB Logo
Predicts cancer drug response using 3D tumoroid tests to guide personalized oncology.
Sweden 2CUREX
4BASEBIO PLC Logo
Manufactures GMP-compliant synthetic DNA for advanced therapies, vaccines, and cell/gene therapies.
United Kingdom 4BB
4SC AG Logo
Developing small-molecule epigenetic drugs for high-need cancer indications.
Germany VSC
Abera Bioscience AB Logo
Develops next-gen mucosal vaccines using its OMV platform, with a lead pneumococcal candidate.
Sweden ABERA
ABINGDON HEALTH PLC Logo
A CDMO for lateral flow rapid tests, providing end-to-end services and its own branded products.
United Kingdom ABDX
ABIONYX Pharma Logo
Biotech developing lipid-based therapies for rare renal and ophthalmological diseases.
France ABNX
Abliva Logo
Develops clinical-stage medicines for rare primary mitochondrial diseases to restore cell function.
Sweden ABLI
AB Science Logo
Develops protein kinase inhibitors for oncology, neuro, and inflammatory diseases.
France AB
Active Biotech Logo
Develops immunology-based drugs for cancer and inflammatory diseases with high unmet medical need.
Sweden ACTI
AcuCort AB Logo
Develops a rapid oral film for acute allergies, croup, and chemo-induced nausea.
Sweden ACUC

Talk to a Data Expert

Have a question? We'll get back to you promptly.